Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?

Even after multiple bellweather wins, Janssen and Bayer still face claims they did not warn doctors about concomitant use with Plavix and aspirin; as case begins in Philadelphia, plaintiff's attorney tells jury the firms were 'silent,' while defense points to doctors' testimony that a different warning would not have changed their prescribing.

court house

PHILADELPHIA – Plaintiff's lawyers hammered one message to the jury in the opening of a Xarelto (rivaroxaban) product liability trial on April 6: Bayer AG and Janssen Pharmaceuticals Inc. were silent about the increased risk of bleeding in those who take the drug with Plavix (clopidogrel) and aspirin, two other blood thinners.

Before beginning his opening statement, Brian Barr, of Levin Papantonio, placed an easel with a large pad of paper in...

More from Drug Safety

More from Pink Sheet

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By 

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

Valneva Expects UK And France to Lift Ixchiq Age Restriction Following EMA Decision

 

Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year